TOCA News and Press, Tocagen From 03/27/19

Sorrento Therapeutics ( SRNE ) was expected to commercialize ZTlido in Q4 2018. In 2019, it should help increase the revenue line and the stock price. In addition, the company should be conducting a Phase 2 trial of anti-CEA CAR-T cell therapy in 2019. On top of it, the most recent merger sign...

NetworkNewsWire Editorial Coverage : Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer. Gene therapies are being developed to more effectively target the tr...

Tocagen Inc. ( TOCA ) is a clinical-stage company engaged in developing selective gene therapy for various cancers. The company's platform uses retroviral replicating vectors technology and its lead drug candidate is a combo of Toca 511 and Toca FC in Phase III clinical trial targeting recurre...

Tocagen (NASDAQ: TOCA ): Q4 GAAP EPS of -$0.96 misses by $0.17 . More news on: Tocagen Inc, Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Feb. 27, 2019 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018 . "We had a very strong cl...

SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its fourth quarter and full year 2018 financial results and business progress on Wednesday, February 27, 2019 , after the close...

NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Retrophin, Inc. (NASDAQ:RTRX), Sunr...

Tocagen ( TOCA ) has a drug in phase 3 trial targeting high grade glioma or HGG. This trial will yield results by the end of 2019. Past early stage trials have shown interesting efficacy data in this difficult to treat cancer. HGG, which includes both stage III gliomas as well as the extremely...

UniQure (NASDAQ: QURE ), Tocagen (NASDAQ: TOCA ), Iovance Biotherapeutics (NASDAQ: IOVA ) and Miragen Therapeutics (NASDAQ: MGEN ) all resumed with Buy ratings at B. Riley FBR. More news on: uniQure N.V., Tocagen Inc, Iovance Biotherapeutics, Inc., Healthcare stocks news, , Tech stocks new...

SAN DIEGO , Nov. 7, 2018 /PRNewswire/ --  Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Marty Duvall , chief executive officer, will present at the following upcoming investor conferences: Wednesday, November ...